Weill Cornell Medicine (WCM) SPORE in Prostate Cancer

威尔康奈尔医学 (WCM) 孢子在前列腺癌中的应用

基本信息

批准号：
10227725
负责人：
Massimo Loda
金额：
$ 212.28万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-30 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10227725
关键词：
Address Biological Markers Biology Biostatistics Core Cancer Biology Caring Center for Translational Science Activities Cessation of life Chronic Clinic Clinical Clinical Medicine Clinical Sciences Clinical Trials Collaborations Communities DNA Repair Data Defect Detection Development Diagnosis Disease Disease Management Disease Progression Drug resistance EZH2 gene Early Detection Research Network Early Diagnosis Ensure Epigenetic Process Faculty Foundations Future Genomics Goals Heterogeneity Indolent Industrialization Infrastructure Institutes International Knowledge Link MYCN gene Malignant Neoplasms Malignant neoplasm of prostate Medicine Mentors Metastatic Prostate Cancer Mission Molecular Mutation Neuroendocrine Prostate Cancer PARP inhibition Pathology Patient Care Patient-Focused Outcomes Patients Precision Medicine Initiative Probability Prognosis Quality of life Reproduction spores Research Research Personnel Resources Risk Assessment Scientist The Cancer Genome Atlas Training Translational Research Translations United States Western World advanced prostate cancer androgen deprivation therapy anticancer research base biomarker-driven cancer care cancer genomics cancer research center director career career development castration resistant prostate cancer clinical biomarkers clinical care clinical risk cohort exome experience improved improved outcome inhibitor/antagonist liquid biopsy men mindfulness multidisciplinary next generation novel novel marker novel strategies novel therapeutic intervention optimal treatments overexpression overtreatment precision medicine preclinical study programs prostate cancer risk radiation response repaired standard of care success translational cancer research translational genomics treatment choice treatment strategy

项目摘要

OVERALL SUMMARY Prostate cancer (PCA) is one of the most common cancers in the Western hemisphere, with extreme clinical and molecular heterogeneity. In 2015, over 221,800 men were diagnosed with—and 27,540 died from—PCA in the United States. Our Weill Cornell Medicine (WCM) SPORE in PCA will take a novel precision medicine approach to patient care, which will align our translational research goals with the care of men across the PCA spectrum. The earliest possible detection of aggressive PCA will avoid less effective late-stage therapies. We will study how to improve risk assessment in men with localized PCA to enable optimal treatment choices, including active surveillance (AS). Men with advanced PCA, despite treatment with next generation androgen deprivation therapy (ADT), succumb to drug resistance and disease progression. We need to optimize care through novel biomarker and treatment strategies to change lethal PCA to a chronic manageable disease. We are mindful that knowledge from other fields can augment our research. We will actively use the Developmental Research Program to bring investigators from across a rich, multi-institutional landscape to focus on PCA translational research. A sustainable SPORE program requires development of the careers of junior faculty (Career Enhancement Program), who will be the leaders in the field for years to come. Horizontal and vertical scientific collaborations will ensure that we leverage expertise and experience across other SPOREs, the Early Detection Research Network (EDRN), and the Stand Up 2 Cancer (SU2C) and Prostate Cancer Foundation (PCF) programs. Lastly, we will ensure that resources and data generated from our studies will be made available to the research community. Our overarching goal is to impact PCA care from initial diagnosis through management of advanced state disease using precision medicine approaches to improve current clinical care. In summary, the WCM SPORE in PCA will be a major hub for paradigm-shifting translational research. We will establish new approaches to treating PCA, which will result in improved patient survival and quality of life.

总体总结前列腺癌（PCA）是西半球最常见的癌症之一，临床发病率极高 2015 年，超过 221,800 名男性被诊断患有 PCA，其中 27,540 人死于 PCA。美国我们威尔康奈尔医学（WCM）SPORE在PCA上会采取一种新颖的精准医学。患者护理方法，这将使我们的转化研究目标与 PCA 中男性的护理保持一致尽早检测侵袭性 PCA 将避免效果较差的后期治疗。将研究如何改进患有局部 PCA 的男性的风险评估，以实现最佳的治疗选择，包括尽管接受下一代雄激素治疗但仍患有晚期 PCA 的男性。剥夺疗法（ADT），屈服于耐药性和疾病进展，我们需要优化护理。通过新的生物标志物和治疗策略，将致命的 PCA 转变为可控制的慢性疾病。我们注意到其他领域的知识可以增强我们的研究，我们将积极利用这些知识。发展研究计划将来自丰富的多机构环境的研究人员带到专注于 PCA 转化研究可持续的 SPORE 计划需要发展职业生涯。初级教师（职业提升计划），他们将在未来几年成为该领域的领导者。垂直科学合作将确保我们利用其他人的专业知识和经验 SPORE、早期检测研究网络 (EDRN) 以及 Stand Up 2 癌症 (SU2C) 和前列腺最后，我们将确保我们的研究产生的资源和数据。我们的总体目标是从最初的阶段就影响 PCA 护理。通过使用精准医学方法管理晚期疾病来进行诊断，以改善目前的临床护理。总之，PCA 中的 WCM SPORE 将成为范式转变转化研究的主要中心。建立治疗 PCA 的新方法，这将提高患者的生存率和生活质量。

项目成果

期刊论文数量（54）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations.

DOI：
10.1158/0008-5472.can-22-2236
发表时间：
2023-04-14
期刊：
Cancer research
影响因子：
11.2
作者：
通讯作者：

REPAC: analysis of alternative polyadenylation from RNA-sequencing data.

DOI：
10.1186/s13059-023-02865-5
发表时间：
2023-02-09
期刊：
Genome biology
影响因子：
12.3
作者：
通讯作者：

"Stromal cells in prostate cancer pathobiology: friends or foes?".

DOI：
10.1038/s41416-022-02085-x
发表时间：
2023-04
期刊：
British journal of cancer
影响因子：
8.8
作者：
Pederzoli F;Raffo M;Pakula H;Ravera F;Nuzzo PV;Loda M
通讯作者：
Loda M

Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.

DOI：
10.1158/1541-7786.mcr-23-0045
发表时间：
2023-06-01
期刊：
MOLECULAR CANCER RESEARCH
影响因子：
5.2
作者：
Venkadakrishnan, Varadha Balaji;Yamada, Yasutaka;Weng, Kenny;Idahor, Osasenaga;Beltran, Himisha
通讯作者：
Beltran, Himisha

Charting differentially methylated regions in cancer with Rocker-meth.

DOI：
10.1038/s42003-021-02761-3
发表时间：
2021-11-02
期刊：
Communications biology
影响因子：
5.9
作者：
Benelli M;Franceschini GM;Magi A;Romagnoli D;Biagioni C;Migliaccio I;Malorni L;Demichelis F
通讯作者：
Demichelis F